Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|December 1, 2010
AAPS 2010 Science Award Winners: Pavan Vaddady
Advertisement
A Joint Presentation of Pharmaceutical Technology and
Interviews with the 2010 AAPS Science Award Winners
Pavan Vaddady
PhD candidate, Pharmaceutical Sciences, University of Tennessee Health Science Center.
Award: Eli Lilly Graduate Student Symposium Award in Pharmacokinetics, Pharmacodynamics, Drug Metabolism and Clinical Pharmacology and Translational Research for research in "Pharmacokinetic Evaluation of a Novel Spectinamide Series of Antituberculosis Agents"
View Full Research Presentation
Winners
Listen to the Interviews
AAPS President
Dr. Danny Shen, president of AAPS, discusses the level of scientific innovation and industry trends.
Listen>>
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement